Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006864 · ClinicalTrials.gov registry record · Phase 4

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

A Phase 4 study of Kidney Cancer, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
Phase 4
Development phase
2
Study locations

NCT00006864: Completed Phase 4 study of Kidney Cancer, sponsored by Case Comprehensive Cancer Center.

NCT00006864 is a Phase 4 study of Kidney Cancer that has completed, run by Case Comprehensive Cancer Center. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006864, a Phase 4 study of Kidney Cancer, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 4
Development phase
2
Study locations

Study Summary

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase IV trial to study the effectiveness of interleukin-2 in treating patients who have metastatic kidney cancer.

Conditions Studied

Interventions

  • BIOLOGICAL aldesleukin

Study Locations (2)

Connecticut

  • Northwestern Connecticut Oncology-Hematology Associates - Torrington

Ohio

  • Ireland Cancer Center - Cleveland

Trial Details

FieldValue
Start Date 2000-07
Est. Completion 2007-07
Phase Phase 4
Case Comprehensive Cancer Center

407 total trials

What the finished NCT00006864 record still lists

NCT00006864 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 1 intervention - of which aldesleukin is the first listed.

NCT00006864 reports a single indexed study location in Connecticut, Ohio.

Frequently Asked Questions

What is clinical trial NCT00006864 about?

NCT00006864 is a clinical study titled "Interleukin-2 in Treating Patients With Metastatic Kidney Cancer". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase IV trial to study the effectiveness of interleukin-2 in treating patients who have metastatic kidney cancer.

What is the current status of trial NCT00006864?

This trial is currently completed. It is a Phase 4 study. The study started on 2000-07. Estimated completion is 2007-07.

What conditions does trial NCT00006864 study?

This clinical trial studies the following conditions: Kidney Cancer.

What interventions are being tested in trial NCT00006864?

The interventions under investigation include: aldesleukin (BIOLOGICAL).

Who is sponsoring clinical trial NCT00006864?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00006864 being conducted?

This trial has 2 study locations across Connecticut, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00006864, the US trial registry maintained by the National Library of Medicine. NCT00006864 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.